Detalhe da pesquisa
1.
Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial.
Neurol Neuroimmunol Neuroinflamm
; 10(4)2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37094998
2.
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
Neurol Neuroimmunol Neuroinflamm
; 10(4)2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37258412